A carregar...
Bifeprunox versus placebo for schizophrenia
BACKGROUND: Bifeprunox is a novel antipsychotic drug designed to treat schizophrenia. However, research into the drug was ceased in 2009 due to rejection of licence to go to market by the US Food and Drug Administration (FDA), who could not approve the drug for acute or long‐term symptoms of schizop...
Na minha lista:
| Publicado no: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Ltd
2016
|
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6457956/ https://ncbi.nlm.nih.gov/pubmed/27732740 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012029.pub2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|